TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29540427

Group type: EXPERIMENTAL
Intervention: Higher (moderate-high)-intensity statins (n=868)
Number of subjects: 2444

Group type: EXPERIMENTAL
Intervention: Lower (low)-intensity statins (n=526)
Number of subjects: 2444

Group type: COMPARATOR
Intervention: No statin (n=1050)
Number of subjects: 2444
Study: 29540492

Group type: EXPERIMENTAL
Intervention: Percutaneous left atrial appendage (LAA) closure
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Overall health status consideration during preprocedural evaluation
Number of subjects: 436
Study: 29540575

Group type: EXPERIMENTAL
Intervention: Apolipoprotein E isoforms (apoE2, apoE3, apoE4)
Number of subjects: 0
Study: 29540603

Group type: EXPERIMENTAL
Intervention: Weekly docetaxel, cisplatin, and cetuximab (TPC)
Number of subjects: 29
Study: 29541050

Group type: EXPERIMENTAL
Intervention: School-based physical activity intervention
Number of subjects: 360

Group type: COMPARATOR
Intervention: Executive function, behavioral self-regulation, and school related well-being
Number of subjects: 360
Study: 29541481

Group type: EXPERIMENTAL
Intervention: Peer Empowerment And Remote communication Linked by information technology (PEARL) intervention
Number of subjects: 628

Group type: COMPARATOR
Intervention: No peer support (control group)
Number of subjects: 628
Study: 29541875

Group type: EXPERIMENTAL
Intervention: Functional connectivities (FCs) between the dorsal dysgranular insula (dId) and other brain regions in males
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Functional connectivities (FCs) between the left dId and specific brain regions in males
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Functional connectivities (FCs) between the left dId and the right rostral anterior cingulate cortex in males
Number of subjects: 37
Study: 29541969

Group type: EXPERIMENTAL
Intervention: Electrocardiographic global electrical heterogeneity (GEH) measures including spatial QRST angle, spatial ventricular gradient magnitude, azimuth, elevation, and sum absolute QRST integral.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GEH ECG risk score.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sustained ventricular tachyarrhythmia event with appropriate ICD therapy.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All-cause death without preceding sustained ventricular tachyarrhythmia with appropriate ICD therapy.
Number of subjects: 0
Study: 29542012

Group type: EXPERIMENTAL
Intervention: LY IGlar
Number of subjects: 756

Group type: COMPARATOR
Intervention: SA IGlar
Number of subjects: 756
Study: 29542886

Group type: EXPERIMENTAL
Intervention: ICS/LABA combined therapy
Number of subjects: 505
Study: 29543115

Group type: EXPERIMENTAL
Intervention: High PAC in middle-SES children
Number of subjects: 1157

Group type: EXPERIMENTAL
Intervention: High PAC in low-SES children
Number of subjects: 1157

Group type: EXPERIMENTAL
Intervention: Middle-SES children with high PAC
Number of subjects: 1157

Group type: COMPARATOR
Intervention: Low-SES children
Number of subjects: 1157
Study: 29543490

Group type: EXPERIMENTAL
Intervention: Parent and adolescent reports of diabetes-specific family conflict
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Discrepancies between parent and adolescent reports of family conflict
Number of subjects: 120
Study: 29543932

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously every 3 weeks until disease progression or unacceptable toxic effects
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Pembrolizumab in PD-L1-positive tumors
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Pembrolizumab in PD-L1-negative tumors
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 259
Study: 29544445

Group type: EXPERIMENTAL
Intervention: Trastuzumab (Herceptin®) therapy
Number of subjects: 25
Study: 29544454

Group type: EXPERIMENTAL
Intervention: Niclosamide 2 g orally once a day until disease progression or toxicity
Number of subjects: 0
Study: 29544547

Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 260

Group type: COMPARATOR
Intervention: Best Available Therapy (BAT)
Number of subjects: 260
Study: 29544552

Group type: EXPERIMENTAL
Intervention: Older individuals
Number of subjects: 108183

Group type: EXPERIMENTAL
Intervention: Individuals with primary education
Number of subjects: 108183

Group type: EXPERIMENTAL
Intervention: Female employees and self-employed women
Number of subjects: 108183

Group type: EXPERIMENTAL
Intervention: Middle-aged subjects
Number of subjects: 108183

Group type: EXPERIMENTAL
Intervention: Presence of a child in the household
Number of subjects: 108183

Group type: EXPERIMENTAL
Intervention: Low income individuals and manual workers
Number of subjects: 108183

Group type: EXPERIMENTAL
Intervention: Women with low education level
Number of subjects: 108183

Group type: EXPERIMENTAL
Intervention: Low socioeconomic categories and young adults
Number of subjects: 108183
Study: 29544613

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0
Study: 29544699

Group type: EXPERIMENTAL
Intervention: 6-month DAPT
Number of subjects: 2712

Group type: COMPARATOR
Intervention: 12-month or longer DAPT
Number of subjects: 2712
Study: 29545095

Group type: EXPERIMENTAL
Intervention: Durvalumab (10 mg/kg) every 2 weeks for up to 12 months
Number of subjects: 444
Study: 29545231

Group type: EXPERIMENTAL
Intervention: 25 IU/kg plasma-derived factor X (pdFX)
Number of subjects: 6
Study: 29545283

Group type: EXPERIMENTAL
Intervention: Multi-omics integration using nine omics data blocks (mRNA, micro RNA, proteomes, and metabolomes)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Integration of five to seven omics data blocks
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Seven different combinations of four to seven omics platforms
Number of subjects: 52
Study: 29545734

Group type: EXPERIMENTAL
Intervention: NORDIET-FFQ
Number of subjects: 81
Study: 29545772

Group type: EXPERIMENTAL
Intervention: Degarelix (0.5 ml bolus injection)
Number of subjects: 10
Study: 29545951

Group type: EXPERIMENTAL
Intervention: Botox injections in HFS patients
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy volunteers without Botox injections
Number of subjects: 24
Study: 29545953

Group type: EXPERIMENTAL
Intervention: Selective retina therapy (SRT) with real-time feedback-controlled dosimetry
Number of subjects: 16
Study: 29546247

Group type: EXPERIMENTAL
Intervention: Twice-weekly in-person and telephone-based guidance on calorie-restricted diets and aerobic exercise
Number of subjects: 40

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 40
Study: 29546316

Group type: EXPERIMENTAL
Intervention: High-fat meal (HFM)
Number of subjects: 2
Study: 29546671

Group type: EXPERIMENTAL
Intervention: Endoscopy
Number of subjects: 228

Group type: COMPARATOR
Intervention: Radiologic examination using water-soluble contrast (1st group)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Endoscopy (2nd group)
Number of subjects: 228
Study: 29547638

Group type: EXPERIMENTAL
Intervention: Conventional reused ventilator system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Disposable closed ventilator-suction system
Number of subjects: 0
Study: 29548277

Group type: EXPERIMENTAL
Intervention: Common variants in hERG (rs36210421 and rs1805123)
Number of subjects: 7224
Study: 29548287

Group type: EXPERIMENTAL
Intervention: Locally produced ready-to-use supplementary food (RUSF)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Corn-Soy Blend Plus Plus (CSB++)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Sprinkles micronutrient powders
Number of subjects: 540

Group type: COMPARATOR
Intervention: Unimproved diet
Number of subjects: 540
Study: 29548300

Group type: EXPERIMENTAL
Intervention: PTH 1-34 + WBV-exercise
Number of subjects: 40

Group type: COMPARATOR
Intervention: PTH 1-34
Number of subjects: 40
Study: 29548305

Group type: EXPERIMENTAL
Intervention: Cigarette smoke extract (CSE) exposure in bronchial epithelial cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CC16 immunostaining intensity in bronchial epithelium
Number of subjects: 0
Study: 29548561

Group type: EXPERIMENTAL
Intervention: Three-dimensional conformal radiation therapy (3-DCRT)
Number of subjects: 35
Study: 29548608

Group type: EXPERIMENTAL
Intervention: Trivalent influenza vaccine (TIV)
Number of subjects: 3394
Study: 29548752

Group type: EXPERIMENTAL
Intervention: Vitamin D concentration
Number of subjects: 1191
Study: 29548900

Group type: EXPERIMENTAL
Intervention: Cataract surgery (phacoemulsification and intraocular lens implantation)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 26
Study: 29548934

Group type: EXPERIMENTAL
Intervention: 1.8 mg liraglutide once daily
Number of subjects: 62

Group type: COMPARATOR
Intervention: 4 mg glimepiride together with 1 g metformin twice daily
Number of subjects: 62
Study: 29549159

Group type: EXPERIMENTAL
Intervention: Utomilumab (PF-05082566)
Number of subjects: 0
Study: 29549173

Group type: EXPERIMENTAL
Intervention: Splenectomy
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Phototherapy
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Exchange transfusions
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Transfusion until splenectomy
Number of subjects: 254
Study: 29549175

Group type: EXPERIMENTAL
Intervention: Abatacept 3 mg/kg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Abatacept 10 mg/kg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Abatacept (10 mg/kg, expansion cohort)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Abatacept (all doses)
Number of subjects: 16
Study: 29549598

Group type: EXPERIMENTAL
Intervention: Adapalene 0.3% gel, applied once daily for the first 4 weeks and twice daily for the following 20 weeks.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adapalene 0.3% gel
Number of subjects: 0
Study: 29549862

Group type: EXPERIMENTAL
Intervention: gemcitabine plus erlotinib (gem/erlotinib)
Number of subjects: 150

Group type: COMPARATOR
Intervention: FOLFIRINOX (for patients switched from gem/erlotinib)
Number of subjects: 150
Study: 29550052

Group type: EXPERIMENTAL
Intervention: Topological Data Analysis (TDA)
Number of subjects: 202
Study: 29550177

Group type: EXPERIMENTAL
Intervention: Nitinol stents for endovascular reconstruction of the IVC
Number of subjects: 62
Study: 29550195

Group type: EXPERIMENTAL
Intervention: MenACWY-D vaccine in 2-10-year-olds
Number of subjects: 1537

Group type: EXPERIMENTAL
Intervention: MenACWY-D vaccine in 9-23-month-olds
Number of subjects: 1537
Study: 29550259

Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education program for children (PNE4Kids)
Number of subjects: 18
Study: 29550316

Group type: EXPERIMENTAL
Intervention: Culprit lesions
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Noninvasive hemodynamic assessment
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Integration of noninvasive hemodynamic assessments
Number of subjects: 72
Study: 29550319

Group type: EXPERIMENTAL
Intervention: Myocardial shear wave imaging (SWI)
Number of subjects: 80
Study: 29550382

Group type: EXPERIMENTAL
Intervention: Voxtalisib 50 mg orally twice daily in 28-day continuous dosing cycles until progression or unacceptable toxicity
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Voxtalisib 50 mg orally twice daily
Number of subjects: 167
Study: 29550630

Group type: EXPERIMENTAL
Intervention: Plerixafor conditioning regimen
Number of subjects: 18
Study: 29550642

Group type: EXPERIMENTAL
Intervention: Arthroplasty (n=27)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Arthrodesis (n=20)
Number of subjects: 47
Study: 29550773

Group type: EXPERIMENTAL
Intervention: Patients with postoperative delirium (POD)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Patients without postoperative delirium (POD)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Cognition measured by Trails A and B and Stroop Color and Word Test
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Quality of life measured by Veteran's RAND 12-item Health Survey
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Incident dementia measured by Short Blessed Test
Number of subjects: 200
Study: 29551225

Group type: EXPERIMENTAL
Intervention: Flubio® (Influenza HA Trivalent) vaccine, administered in 1 or 2 doses with a 28-day interval.
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Flubio® (Influenza HA Trivalent) vaccine
Number of subjects: 405
Study: 29551311

Group type: EXPERIMENTAL
Intervention: Body Mass Index z-score (BMIZ)
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Changes in BMIZ
Number of subjects: 447
Study: 29551338

Group type: EXPERIMENTAL
Intervention: Sirolimus (2 mg per day, adjusted to maintain a therapeutic range of 6-15 ng/mL) for 12 months
Number of subjects: 40
Study: 29551400

Group type: EXPERIMENTAL
Intervention: Higher scores for food enjoyment and lower scores for satiety responsiveness, slowness in eating, and food fussiness at Time 2
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Higher slowness in eating scores
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Faster eating rates
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Higher BMI children with greater food enjoyment and food responsiveness scores
Number of subjects: 195
Study: 29551401

Group type: EXPERIMENTAL
Intervention: 25-s time delay on the delivery of regular snacks
Number of subjects: 32019

Group type: EXPERIMENTAL
Intervention: $0.25 discount on healthy snacks
Number of subjects: 32019

Group type: EXPERIMENTAL
Intervention: Combination of 25-s time delay and $0.25 discount
Number of subjects: 32019

Group type: EXPERIMENTAL
Intervention: $0.25 tax on regular snacks
Number of subjects: 32019

Group type: EXPERIMENTAL
Intervention: Combination of 25-s time delay and $0.25 tax
Number of subjects: 32019

Group type: COMPARATOR
Intervention: Overall vending sales and revenue
Number of subjects: 32019
Study: 29551407

Group type: EXPERIMENTAL
Intervention: Dietary marine omega-3 PUFA in CHNS
Number of subjects: 50149

Group type: EXPERIMENTAL
Intervention: α-linolenic acid (ALA) in CHNS
Number of subjects: 50149

Group type: EXPERIMENTAL
Intervention: α-linolenic acid (ALA) in NHANES
Number of subjects: 50149

Group type: EXPERIMENTAL
Intervention: Linoleic acid (LA) in NHANES
Number of subjects: 50149

Group type: EXPERIMENTAL
Intervention: Arachidonic acid in NHANES and CHNS
Number of subjects: 50149

Group type: EXPERIMENTAL
Intervention: PUFA at an omega-6/omega-3 ratio of 6-10 in CHNS
Number of subjects: 50149
Study: 29551711

Group type: EXPERIMENTAL
Intervention: Ketamine users
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Sole ketamine users
Number of subjects: 257
Study: 29551775

Group type: EXPERIMENTAL
Intervention: Ilorasertib 40-340 mg orally twice daily (Arm II)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Ilorasertib 10-180 mg orally once daily (Arm I)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Ilorasertib 8-32 mg intravenously once daily (Arm III)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Ilorasertib (all arms)
Number of subjects: 58
Study: 29551893

Group type: EXPERIMENTAL
Intervention: Plasma SFRP5 level
Number of subjects: 1745

Group type: EXPERIMENTAL
Intervention: Low plasma SFRP5
Number of subjects: 1745
Study: 29552014

Group type: EXPERIMENTAL
Intervention: Intralesional (IL) treatment with ipilimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ipilimumab (ICIs)
Number of subjects: 0
Study: 29552321

Group type: EXPERIMENTAL
Intervention: Vemurafenib 960 mg twice daily plus fotemustine 100 mg/m2 intravenously every three weeks
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Vemurafenib 960 mg twice daily plus fotemustine
Number of subjects: 31
Study: 29552356

Group type: EXPERIMENTAL
Intervention: Prolonged-release fampridine (PRF) 10 mg BID
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29552422

Group type: EXPERIMENTAL
Intervention: Diabetes Empowerment Council (DEC) intervention, 12-week holistic, multimodality facilitated group intervention
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Both groups (DEC and control)
Number of subjects: 51
Study: 29552569

Group type: EXPERIMENTAL
Intervention: RRx-001 followed by reintroduction of a platinum doublet after a brief priming period
Number of subjects: 1

Group type: COMPARATOR
Intervention: Platinum doublet regimen
Number of subjects: 1
Study: 29552996

Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 208
Study: 29553382

Group type: EXPERIMENTAL
Intervention: SCA1
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: SCA2
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: SCA3
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: SCA6
Number of subjects: 525
Study: 29553484

Group type: EXPERIMENTAL
Intervention: Intracortical brain-computer interfaces (BCIs)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Features of extracellular waveforms
Number of subjects: 2
Study: 29553852

Group type: EXPERIMENTAL
Intervention: Longitudinal evaluation of carotid intima-media thickness (c-IMT)
Number of subjects: 1284

Group type: EXPERIMENTAL
Intervention: Carotid-femoral pulse wave velocity (PWV)
Number of subjects: 1284

Group type: EXPERIMENTAL
Intervention: Total cholesterol
Number of subjects: 1284

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure
Number of subjects: 1284

Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure
Number of subjects: 1284

Group type: EXPERIMENTAL
Intervention: C-reactive protein
Number of subjects: 1284

Group type: EXPERIMENTAL
Intervention: Lip-line
Number of subjects: 1284

Group type: EXPERIMENTAL
Intervention: Heart rate
Number of subjects: 1284

Group type: EXPERIMENTAL
Intervention: Carotid-femoral PWV
Number of subjects: 1284
Study: 29554265

Group type: EXPERIMENTAL
Intervention: Novel low-profile, 22-Fr transapical delivery system with ACURATE neo™ transcatheter heart valve
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Procedural success in absence of major adverse cardiac and cerebrovascular events at 30 days
Number of subjects: 60
Study: 29555305

Group type: COMPARATOR
Intervention: Any family history (FH)
Number of subjects: 6200

Group type: COMPARATOR
Intervention: Premature family history (FH)
Number of subjects: 6200

Group type: COMPARATOR
Intervention: Strong familial risk assessment (FRA)
Number of subjects: 6200

Group type: COMPARATOR
Intervention: Traditional risk factors
Number of subjects: 6200
Study: 29555620

Group type: EXPERIMENTAL
Intervention: mPCST intervention (Web-based mobile pain coping skills training)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 36
Study: 29555835

Group type: EXPERIMENTAL
Intervention: Quantitative flow ratio (QFR)
Number of subjects: 362

Group type: COMPARATOR
Intervention: Fractional flow reserve (FFR)
Number of subjects: 362
Study: 29555836

Group type: EXPERIMENTAL
Intervention: CT-AVC thresholds for diagnosing severe AS (women 1377 Agatston unit, men 2062 Agatston unit)
Number of subjects: 918

Group type: EXPERIMENTAL
Intervention: CT-AVC thresholds
Number of subjects: 918
Study: 29555989

Group type: EXPERIMENTAL
Intervention: pEBV DNA clearance ≤ 10 days and > 50% drop in sum of SUVmax of target lesions
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Early PET-CT response and pEBV DNA clearance
Number of subjects: 58
Study: 29556158

Group type: EXPERIMENTAL
Intervention: 33% caloric restriction
Number of subjects: 12
Study: 29556414

Group type: EXPERIMENTAL
Intervention: Exoskeleton-assisted gait training (EGT)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Conventional physical therapy (CPT)
Number of subjects: 9
Study: 29556416

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 200 mg every 2 weeks (Q2W)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400 mg every 4 weeks (Q4W)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 409

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 409
Study: 29556419

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 29556418

Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg every 2 weeks plus csDMARDs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus csDMARDs
Number of subjects: 0
Study: 29556695

Group type: EXPERIMENTAL
Intervention: Dasatinib
Number of subjects: 39
Study: 29557387

Group type: EXPERIMENTAL
Intervention: Voltage adjustment during deep brain stimulation
Number of subjects: 6
Study: 29557815

Group type: EXPERIMENTAL
Intervention: Open-label escitalopram for 14 weeks
Number of subjects: 83

Group type: COMPARATOR
Intervention: Healthy control and psychiatric outpatient samples
Number of subjects: 83
Study: 29558160

Group type: EXPERIMENTAL
Intervention: New Ultrasound Method for Estimating Dynamic Intrinsic Positive Airway Pressure
Number of subjects: 0
Study: 29558274

Group type: EXPERIMENTAL
Intervention: Oncologist-led BRCAm testing pathway
Number of subjects: 700
Study: 29558281

Group type: EXPERIMENTAL
Intervention: Veliparib with concurrent radiotherapy (RT) to the chest wall and regional lymph nodes (50 Gy plus a 10-Gy boost)
Number of subjects: 30
Study: 29558533

Group type: EXPERIMENTAL
Intervention: Regular borders
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Irregular borders
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Splitting borders
Number of subjects: 49

Group type: COMPARATOR
Intervention: Comparison between border types
Number of subjects: 49
Study: 29558650

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy (CBGT)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Waitlist (WL)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Emotional clarity changes
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Attention to emotions
Number of subjects: 145
Study: 29558966

Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR) at 35 Gy in 5 fractions
Number of subjects: 12
Study: 29558982

Group type: EXPERIMENTAL
Intervention: HIV-risk-reduction intervention combined with financial literacy intervention, vocational training program, and matched savings (HIVRR+MF)
Number of subjects: 350

Group type: COMPARATOR
Intervention: HIV-risk-reduction intervention alone (HIVRR)
Number of subjects: 350
Study: 29559372

Group type: EXPERIMENTAL
Intervention: Periodic catatonia (PC)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Cataphasia (C)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Schizophrenia (both PC and C)
Number of subjects: 56